Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Citius Pharmaceuticals, Inc. Director's Dealing 2021

Feb 18, 2021

34965_dirs_2021-02-18_48cc88d4-d4ab-45da-83a1-95e0d3e71ebd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2021-02-16

Reporting Person: Dutia Suren G (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-16 Options to Purchase Common Stock $1.69 A 25000 Acquired 2031-02-16 Common Stock (25000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Options to Purchase Common Stock $1.01 2030-10-06 Common Stock (35000) 35000 Direct
Options to Purchase Common Stock $1.39 2030-07-07 Common Stock (25000) 25000 Direct
Options to Purchase Common Stock $0.67 2029-10-08 Common Stock (25000) 25000 Direct
Options to Purchase Common Stock $1.62 2028-09-04 Common Stock (15000) 15000 Direct
Options to Purchase Common Stock $3.45 2027-09-13 Common Stock (10000) 10000 Direct
Options to Purchase Common Stock $8.1 2025-10-01 Common Stock (26667) 26667 Direct

Footnotes

F1: The options vest in full on February 16, 2022.

F2: The options vest in full on October 6, 2021.

F3: The options vest in full on July 7, 2021.

F4: The options vest in full on October 8, 2020.

F5: The options vest in full on September 4, 2019.

F6: The options vest in full on September 13, 2018.

F7: The options granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015.